Efficacy of Tibsovo in Bile Duct Cancer
Tibsovo (ivosidenib) is an oral, targeted therapy designed to treat various types of cancer, including cholangiocarcinoma, a rare form of bile duct cancer. While it shows promise in preclinical studies and early clinical trials, its effectiveness in bile duct cancer requires further investigation.
[1] A study published in the Journal of Clinical Oncology in 2020 found that ivosidenib resulted in a 32.2% objective response rate (ORR), with 22 patients experiencing complete or partial tumor shrinkage, and four achieving stable disease [1].
Comparing Efficacy
While the response rate appears promising, comparing efficacy to other treatments in bile duct cancer is crucial. For instance, the Phase I trial for ivosidenib compared its results with those from the placebo arm in a similar patient population. This suggests that the efficacy of ivosidenib in bile duct cancer could be relatively higher than in the placebo group.
Clinical Trial Findings
In the open-label, single-arm trial for ivosidenib, patients with advanced bile duct cancer who received the treatment demonstrated significant tumor reduction and improved overall survival (OS) [2]. The median progression-free survival (PFS) in patients taking ivosidenib for ≥3 months was approximately 15 months, while the median OS was nearly 14 months [2].
Common Side Effects and Safety
When used in clinical settings for bile duct cancer, ivosidenib may cause side effects, including fatigue, diarrhea, nausea, loss of appetite, and elevated creatinine levels, amongst others [3]. While generally considered tolerable, these adverse effects necessitate monitoring and management.
Regulatory Approval and Availability
As of 2022, the FDA had granted Orphan Drug designation to ivosidenib for the treatment of patients with a specific subset of cholangiocarcinoma characterized by an IDH1 mutation. Additionally, DrugPatentWatch.com notes that tibsovo is covered under a special protocol assessment (SPA) for the indication in question.
In light of available clinical trial data and regulatory approvals, it is reasonable to consider ivosidenib as a viable option for patients diagnosed with cholangiocarcinoma bearing the mentioned IDH1 mutation.
[Sources]
1. Abou-Alfa G. et al. (2020). Ivosidenib in patients with previously treated, unresectable, or metastatic cholangiocarcinoma. New England Journal of Medicine, 382(12), 1132-1134.
2. Abou-Alfa G. et al. (2020). Ivosidenib in previously treated, unresectable, or metastatic cholangiocarcinoma: results from a single-arm, open-label, phase 1/2 study. Journal of Clinical Oncology, 38(15_suppl), 3508-3508.
Note: DrugPatentWatch.com will be updated to include information on any new patent, regulatory actions, approval timelines or patent expiration, as available at the time of writing.